- Home
- HRMY vs NEXT Comparison
HRMY vs NEXT Comparison
Compare HRMY & NEXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- NEXT
- Stock Information
- Founded
- HRMY 2017
- NEXT 2010
- Country
- HRMY United States
- NEXT United States
- Employees
- HRMY N/A
- NEXT N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- NEXT Oil & Gas Production
- Sector
- HRMY Health Care
- NEXT Energy
- Exchange
- HRMY Nasdaq
- NEXT Nasdaq
- Market Cap
- HRMY 1.8B
- NEXT 2.0B
- IPO Year
- HRMY 2020
- NEXT N/A
- Fundamental
- Price
- HRMY $34.94
- NEXT $11.06
- Analyst Decision
- HRMY Strong Buy
- NEXT Buy
- Analyst Count
- HRMY 9
- NEXT 1
- Target Price
- HRMY $55.33
- NEXT $15.00
- AVG Volume (30 Days)
- HRMY 627.0K
- NEXT 2.9M
- Earning Date
- HRMY 08-05-2025
- NEXT 08-01-2025
- Dividend Yield
- HRMY N/A
- NEXT N/A
- EPS Growth
- HRMY 58.41
- NEXT N/A
- EPS
- HRMY 3.10
- NEXT N/A
- Revenue
- HRMY $772,527,000.00
- NEXT N/A
- Revenue This Year
- HRMY $20.45
- NEXT N/A
- Revenue Next Year
- HRMY $17.32
- NEXT N/A
- P/E Ratio
- HRMY $11.29
- NEXT N/A
- Revenue Growth
- HRMY 17.74
- NEXT N/A
- 52 Week Low
- HRMY $26.47
- NEXT $4.27
- 52 Week High
- HRMY $41.61
- NEXT $12.12
- Technical
- Relative Strength Index (RSI)
- HRMY 50.27
- NEXT 58.34
- Support Level
- HRMY $34.09
- NEXT $10.67
- Resistance Level
- HRMY $36.09
- NEXT $11.61
- Average True Range (ATR)
- HRMY 1.42
- NEXT 0.49
- MACD
- HRMY -0.19
- NEXT -0.13
- Stochastic Oscillator
- HRMY 46.42
- NEXT 26.55
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About NEXT NextDecade Corporation
NextDecade Corp is a Houston-based energy company engaged in construction and development activities related to the liquefaction of natural gas and sale of LNG and the capture and storage of CO2 emissions. The group is constructing and developing a natural gas liquefaction and export facility located in the Rio Grande Valley near Brownsville, Texas (the Rio Grande LNG Facility). It also engaged in NEXT Carbon Solutions advancing proprietary processes to lower the cost of utilizing carbon capture and storage (CCS) and help companies reduce their emissions and achieve their clean energy goals.